2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
生物活性
Description
In Vivo
In Vitro
化合物的使用
Kinase Assay
Cell Assay
Animal Administration
参考文献
Brivanib is the hydrolyzed Form of Brivanib alaninate, which is a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
For the detailed information about the solubility of Brivanib (bms-540215) in water, the solubility of Brivanib (bms-540215) in DMSO, the solubility of Brivanib (bms-540215) in PBS buffer, the animal experiment（test） of Brivanib (bms-540215),the in vivo,in vitro and clinical trial test of Brivanib (bms-540215),the cell experiment（test） of Brivanib (bms-540215),the IC50, EC50 and Affinity of Brivanib (bms-540215), please contact DC Chemicals.
-chemical-structure.gif)